Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
McKinsey
Colorcon
McKesson
AstraZeneca

Last Updated: December 2, 2021

DrugPatentWatch Database Preview

Patent: 8,852,877

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 8,852,877
Title:Apparatus and method for identifying a hook effect and expanding the dynamic range in point of care immunoassays
Abstract: The present invention relates to systems and methods for the rapid in situ determination of the existence of a hook effect and expansion of the dynamic range of a point of care immunoassay. For example, a system for identifying a hook effect and expanding the dynamic range of an immunoassay is provided that may include a primary sensor having first immobilized antibodies that may be configured to generate a first signal based on a presence or absence of a target analyte in a sample. The system may further include an attenuated sensor having second immobilized antibodies at a reduced concentration relative to a concentration of the first immobilized antibodies on the primary sensor and that may be configured to generate a second signal based on the presence or absence of the target analyte in the sample. The system may further include a processor configured to determine a presence of a hook effect in the immunoassay based on relative values of the first and second signals and optionally determine the target analyte concentration of the sample.
Inventor(s): Campbell; John (Woodlawn, CA), Nguyen; Linda (Gloucester, CA), Smith; James (North Gower, CA), Weiss; Wenda (Munster, CA)
Assignee: Abbott Point of Care Inc. (Princeton, NJ)
Application Number:14/141,837
Patent Claims:see list of patent claims

Details for Patent 8,852,877

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1974-01-15 ⤷  Free Forever Trial 2032-12-28
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1984-12-27 ⤷  Free Forever Trial 2032-12-28
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1985-02-15 ⤷  Free Forever Trial 2032-12-28
Ferring Pharmaceuticals Inc. NOVAREL chorionic gonadotropin For Injection 017016 1990-02-16 ⤷  Free Forever Trial 2032-12-28
Bel-mar Laboratories, Inc. CHORIONIC GONADOTROPIN chorionic gonadotropin Injection 017054 1974-03-26 ⤷  Free Forever Trial 2032-12-28
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Johnson and Johnson
Harvard Business School
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.